The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch of therapies such as AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat […]
The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, and rising awareness of targeted therapies. Additionally, growing investment in research and development, along with the launch of […]
The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line treatments. Advances in targeted therapies and immunotherapies […]
The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line treatments. Advances in targeted therapies and immunotherapies […]
The AHR agonist market is experiencing growth, driven by the rising awareness of AHR’s involvement in immune regulation, skin barrier restoration, and microbiome interactions. The approval of VTAMA for treating both plaque psoriasis and atopic […]
